Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of Ig NextGen 16% Administered by Subcutaneous Infusion in Patients With Primary Immunodeficiency (PID).

NCT00680446 is registered in ClinicalTrials.gov with CSL Limited as lead sponsor.

NCT NCT00680446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00680446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of Ig NextGen 16% Administered by Subcutaneous Infusion in Patients With Primary Immunodeficiency (PID).
Lead sponsor
CSL Limited
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2008
Completion date
May 31, 2013
Enrollment
41 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune deficiency